The introduction of nicotinamide to be a nicotine replacement in e-cigarette and smokeless products and solutions represents a substantial regulatory challenge with the FDA. Nicotinamide doesn't have nicotinic receptor agonist exercise and is known to work as a sedative at significant dosages6.